Ovid Therapeutics Inc (FRA:1OT)
€ 1.05 0.04 (3.96%) Market Cap: 77.02 Mil Enterprise Value: 20.38 Mil PE Ratio: 0 PB Ratio: 0.94 GF Score: 34/100

Ovid Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 19, 2021 / 01:10PM GMT
Release Date Price: €3.08 (+4.05%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Good morning, everyone. I'm Brian Abrahams, senior biotech analyst here at RBC Capital Markets, and welcome again to day 2 of our healthcare conference.

Our next presenting company is Ovid Therapeutics, represented by their CEO and Chairman of the Board, Jeremy Levin. Jeremy thanks again for joining us.

Jeremy Max Levin
Ovid Therapeutics Inc. - Chairman & CEO

Brian, thanks a lot. Pleasure being here with you. Nice to see you at least on video. It'd be fun to see you face to face.

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Sure, would, hopefully soon.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

So a lot going on at Ovid these days. You recently closed your amended deal with Takeda. Can you maybe talk a little bit more about that and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot